Which statement best describes what the ICH E6(R3) Guideline aims to harmonize?

• A. It aims to standardize pharmacokinetic modeling approaches.
• B. It aims to standardize funding mechanisms for trials.
• C. It aims to harmonize regulatory expectations across regions to ensure ethical and scientific quality.
• D. It aims to harmonize the branding of pharmaceutical companies.

Answer: (C)

The central idea here is that this guideline aims to align what regulators in different regions expect for clinical trials, so that trials are conducted ethically and with scientific quality. By harmonizing these regulatory expectations, sponsors can design and conduct studies that meet consistent standards no matter where the trial takes place, which supports participant protection, data integrity, and reliable results.

The other options wander into areas outside the guideline’s purpose. Standardizing pharmacokinetic modeling approaches isn’t the goal of this harmonization effort, nor is aligning funding mechanisms or branding of companies.